Needham & Company LLC Reaffirms “Buy” Rating for Dermira (NASDAQ:DERM)

Dermira (NASDAQ:DERM)‘s stock had its “buy” rating restated by equities researchers at Needham & Company LLC in a report released on Friday, AnalystRatings.com reports. They currently have a $22.00 target price on the biopharmaceutical company’s stock. Needham & Company LLC’s price objective would suggest a potential upside of 207.26% from the company’s current price.

Several other equities analysts also recently weighed in on the company. Zacks Investment Research upgraded Dermira from a “hold” rating to a “strong-buy” rating and set a $6.50 target price on the stock in a research report on Wednesday, October 9th. BidaskClub downgraded Dermira from a “sell” rating to a “strong sell” rating in a research report on Saturday, October 12th. Two research analysts have rated the stock with a sell rating, one has issued a hold rating, eight have given a buy rating and one has given a strong buy rating to the company. Dermira presently has an average rating of “Buy” and an average price target of $17.36.

NASDAQ DERM opened at $7.16 on Friday. The business’s 50-day moving average price is $7.22 and its 200 day moving average price is $9.22. Dermira has a twelve month low of $5.25 and a twelve month high of $15.48. The company has a market capitalization of $309.52 million, a PE ratio of -1.37 and a beta of 1.32. The company has a current ratio of 8.42, a quick ratio of 8.08 and a debt-to-equity ratio of 4.95.

Dermira (NASDAQ:DERM) last released its earnings results on Wednesday, August 7th. The biopharmaceutical company reported ($0.33) earnings per share for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.90) by $0.57. Dermira had a negative return on equity of 478.29% and a negative net margin of 306.91%. The firm had revenue of $66.65 million for the quarter, compared to the consensus estimate of $34.16 million. Equities analysts predict that Dermira will post -4.42 EPS for the current year.

In other news, CEO Thomas G. Wiggans purchased 23,419 shares of the company’s stock in a transaction on Monday, August 19th. The stock was bought at an average cost of $8.54 per share, for a total transaction of $199,998.26. Following the completion of the purchase, the chief executive officer now directly owns 39,666 shares of the company’s stock, valued at approximately $338,747.64. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, Director Matthew K. Fust sold 6,000 shares of the company’s stock in a transaction dated Thursday, September 12th. The stock was sold at an average price of $8.77, for a total value of $52,620.00. Following the sale, the director now owns 11,051 shares of the company’s stock, valued at $96,917.27. The disclosure for this sale can be found here. Corporate insiders own 12.40% of the company’s stock.

A number of large investors have recently made changes to their positions in DERM. Point72 Hong Kong Ltd increased its stake in Dermira by 124.2% during the second quarter. Point72 Hong Kong Ltd now owns 4,170 shares of the biopharmaceutical company’s stock worth $40,000 after acquiring an additional 2,310 shares during the last quarter. Bank of Montreal Can increased its stake in Dermira by 621.8% during the second quarter. Bank of Montreal Can now owns 4,533 shares of the biopharmaceutical company’s stock worth $43,000 after acquiring an additional 3,905 shares during the last quarter. Advisor Group Inc. increased its stake in Dermira by 41.7% during the second quarter. Advisor Group Inc. now owns 8,589 shares of the biopharmaceutical company’s stock worth $83,000 after acquiring an additional 2,527 shares during the last quarter. Atria Investments LLC acquired a new stake in Dermira during the second quarter worth about $85,000. Finally, Fox Run Management L.L.C. acquired a new stake in Dermira during the second quarter worth about $120,000. Institutional investors own 94.53% of the company’s stock.

Dermira Company Profile

Dermira, Inc, a biopharmaceutical company, develops and commercializes therapies for patients with dermatologic diseases in the United States. The company offers QBREXZA, a topical once-daily anticholinergic cloth for the treatment of primary axillary hyperhidrosis in adult and pediatric patients nine years of age and older.

See Also: Trading Strategy Examples and Plans

Analyst Recommendations for Dermira (NASDAQ:DERM)

Receive News & Ratings for Dermira Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Dermira and related companies with MarketBeat.com's FREE daily email newsletter.